Zura Bio Limited (ZURA)

Market Cap	245.12M
Revenue (ttm)	n/a
Net Income (ttm)	-65.43M
Shares Out	65.02M
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	411,326
Open	3.910
Previous Close	3.930
Day's Range	3.720 - 3.930
52-Week Range	0.970 - 4.900
Beta	0.25
Analysts	Buy
Price Target	11.00 (+191.78%)
Earnings Date	Nov 7, 2025

About ZURA

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2022
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: ZURA
• Website: https://zurabio.com

Analyst Summary

According to 9 analysts, the average rating for ZURA stock is "Buy." The 12-month stock price target is $11.0, which is an increase of 191.78% from the latest price.

Price Target

$11.0

(191.78% upside)

Analyst Consensus: Buy